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Urinary peptidomics analysis 
reveals proteases involved in 
diabetic nephropathy
Magdalena Krochmal  1, Georgia Kontostathi1, Pedro Magalhães2,3, Manousos Makridakis1, 
Julie Klein4,5, Holger Husi  6, Johannes Leierer7, Gert Mayer7, Jean-Loup Bascands8,  
Colette Denis4,5, Jerome Zoidakis1, Petra Zürbig2, Christian Delles  9, Joost P. Schanstra4,5, 
Harald Mischak2,9 & Antonia Vlahou1
Mechanisms underlying the onset and progression of nephropathy in diabetic patients are not fully 
elucidated. Deregulation of proteolytic systems is a known path leading to disease manifestation, 
therefore we hypothesized that proteases aberrantly expressed in diabetic nephropathy (DN) 
may be involved in the generation of DN-associated peptides in urine. We compared urinary 
peptide profiles of DN patients (macroalbuminuric, n = 121) to diabetic patients with no evidence 
of DN (normoalbuminuric, n = 118). 302 sequenced, differentially expressed peptides (adjusted 
p-value < 0.05) were analysed with the Proteasix tool predicting proteases potentially involved in 
their generation. Activity change was estimated based on the change in abundance of the investigated 
peptides. Predictions were correlated with transcriptomics (Nephroseq) and relevant protein expression 
data from the literature. This analysis yielded seventeen proteases, including multiple forms of MMPs, 
cathepsin D and K, kallikrein 4 and proprotein convertases. The activity of MMP-2 and MMP-9, predicted 
to be decreased in DN, was investigated using zymography in a DN mouse model confirming the 
predictions. Collectively, this proof-of-concept study links urine peptidomics to molecular changes 
at the tissue level, building hypotheses for further investigation in DN and providing a workflow with 
potential applications to other diseases.
Diabetic nephropathy (DN) remains the leading cause of end-stage renal disease worldwide, contributing to 
mortality in affected patients1,2. Moreover, deterioration of kidney function is associated with severe cardiovas-
cular events in diabetic patients3. Current diagnostic tools for DN include measurement of glomerular filtration 
rate (GFR) and urinary albumin excretion rate (AER), however both markers lack the ability to reliably predict 
disease progression4.
Investigation of molecular pathways affected in DN can provide new insights regarding disease pathophys-
iology and assessment of onset and disease progression. Intracellular maintenance of protein homeostasis has 
been attributed to cooperation between molecular chaperones and proteases5. Altered protease activation and 
protease-dependent signalling has been linked to hallmarks of kidney disease such as inflammation and tissue 
remodelling6. Multiple studies suggest that high glucose levels are related to inhibition of matrix metalloprotein-
ases (MMPs), leading to accumulation of extracellular matrix (ECM) in the kidney tissue7. Along these lines, 
high activity of dipeptidyl peptidase-4 (DPP-4), a multifunctional cell surface aminopeptidase, was suggested to 
contribute to renal fibrosis in DN and its inhibition showed renoprotective effects in recent studies8,9. Moreover, 
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pronounced hypertension induced by proteolytic activation of the epithelial sodium channel (ENaC) was found 
related to increased renal filtration of plasminogen (activated to plasmin in urine), prostasin and urokinase10. 
Undoubtedly, proteases play a significant role in pathogenesis of DN, however, given the complexity of proteolytic 
systems, further research efforts are required to gain a broader view of their function in the disease.
In the era of high-throughput technologies, increasing effort is placed on discovery and development of 
non-invasive biomarkers. A prominent example of such projects is the development of a urinary peptide bio-
marker panel, the CKD 273 classifier, for diagnosis of chronic kidney disease (CKD) progression11. Moving one 
step further, recently published studies aim at elucidating the mechanism responsible for the generation of uri-
nary peptides and therefore identify probable biological pathways altered at the tissue level12,13.
The aim of this study was to predict proteases involved in the generation of urinary peptides differen-
tially expressed in DN patients in comparison to diabetic controls exhibiting normal urinary albumin levels. 
Furthermore, algorithms were developed to estimate in silico the activity trend of the deregulated proteases. 
Predicted findings were investigated in the context of available kidney tissue transcriptomics data and relevant 
literature and, in selected cases, validated by gelatin zymography in DN mouse models. Therefore, this study pro-
vides an integrated workflow and can serve as a proof of principle for linking urinary peptidomics data to tissue 
events in DN, ultimately providing a path towards liquid biopsy in nephrology14.
Results
Differentially Expressed Peptides. The main steps of the study are outlined in Fig. 1. The analysis 
focused on comparison of urinary peptides in diabetic patients with nephropathy (n = 121, urinary albumin 
levels >300 mg/L, DN) vs. patients without evidence of DN (n = 118, urinary albumin levels <30 mg/L, non-DN; 
Table 1). Out of a total of 1385 detected peptides, 302 peptides were found to be differentially abundant at sta-
tistically significant levels (pval < 0.05, following adjustment for multiple testing) and with an over 50% change 
in abundance in DN urine samples in comparison to controls (Supplementary Table 1). These included multiple 
fragments of alpha-1 antitrypsin (41 fragments, including isoforms carrying different post-translational modi-
fications such as peptide IDs 40409 and 38879), collagen A1 (I) (57 fragments), collagen A2 (I) (10 fragments), 
collagen A1 (III) (34 fragments), beta-2-microglobulin (14 fragments), but also fragments of serum albumin, 
various apolipoproteins (I, II, IV), fibrinogen and uromodulin (Supplementary Table 1). Of these peptides, 117 
were found at lower and 185 at higher levels in DN versus non-DN group. The distribution of deregulated pep-
tides based on protein of origin is presented in Table 2.
Figure 1. Project workflow and main results.
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Protease Prediction and Activity Calculation. Protease prediction with Proteasix15 (www.proteasix.org) 
was performed applying stringent criteria (only accepting proteases with experimentally observed cleavage sites, 
as described in the Methods section), which yielded a list of 30 proteases putatively responsible for the generation 
of the 302 differentially expressed urinary peptides (Supplementary Table 2). Given the broad substrate specific-
ity of most proteases16, one protease could be assigned to different peptide sequences (e.g. predicted cleavage of 
hemoglobin subunit alpha, hemoglobin subunit beta and osteopontin by cathepsin D) and conversely, one pep-
tide sequence could be cleaved by different proteases (e.g. predicted cleavage of collagen alpha-2 (I) [844–865] 
fragment by MMP-2, MMP-13, MMP-14). For the 30 proteases, a total of 135 associated peptides (corresponding 
to 53 unique peptide IDs) and their regulation trend were extracted from the input list (Supplementary Table 2). 
An activity score was then calculated (described in the Methods section) potentially reflecting the predicted 
alteration in catalytic activity of each protease (Table 3, Supplementary Table 3). A threshold of a minimum of 
3 associated peptides per protease was applied to increase reliability of prediction, which resulted in a final list 
of 17 deregulated proteases (Table 3). Among the highest scoring proteases predicted to have increased proteo-
lytic activity are cathepsin D (CTSD), kallikrein 4 (KLK4), proprotein convertases (PCSK4, PCSK5, PCSK6 and 
PCSK7) and matrix metalloproteinase-7 (MMP-7). Potentially inhibited proteases included various matrix met-
alloproteinases i.e. MMP-13, MMP-9, MMP-2, MMP-3, MMP-8 and MMP-12. Predicted proteases together with 
the respective calculated activity scores are presented in Table 3.
Validation of Predictions. Cross-omics correlations in Nephroseq database. To place our predictions in 
the context of existing literature in the field and compile relevant evidence, as a first step, kidney transcriptomics 
data from DN patients and healthy controls were retrieved from the Nephroseq database (www.nephroseq.org) 
and the mRNA level of expression of the 17 predicted proteases in DN was evaluated. In total, 5 profiling data-
sets comparing DN vs. healthy control subjects were found in the database, from which protease transcripts 
(pval < 0.05 in DN vs. controls) were extracted. Those datasets originated from 3 scientific publications related 
to DN i.e. Ju et al.17, Schmid et al.18 and Woroniecka et al.19 (summarized in Supplementary Table 4). We found 
a total of 12 protease transcripts overlapping with the 17 predicted proteases (Table 3 and Supplementary 
Table 5). The predicted protease activity trend was in agreement with the respective mRNA expression trend for 
With albuminuria 
(Ualb >300 mg/L)
Without albuminuria 
(Ualb <30 mg/L) P-value
N 121 118 —
Age 58 ± 13 58 ± 13 0.989
Male/Female 80/41 82/36 1
DM Type 1/Type 2 47/74 47/71 0.357
HbA1c 9.1 ± 2.0 7.9 ± 1.6 0.024
Urine albumin (mg/L) 880 ± 760 10.8 ± 7.5 <0.001
Creatinine (mg/dl) 1.58 ± 0.89 1.05 ± 0.36 <0.001
SBP 144 ± 20 133 ± 19 <0.001
DBP 80 ± 10 76 ± 10 0.001
eGFR (ml/min/1.73 m2) 68 ± 36 76 ± 27 0.034
LDL (mmol/L) 2.3 ± 1.0 2.3 ± 0.7 0.688
HDL (mmol/L) 1.1 ± 0.5 1.5 ± 0.5 0.497
Table 1. Clinical characteristics of the patients. Abbreviations: Ualb – urine albumin, SBP - Systolic Blood 
Pressure, DBP - Diastolic Blood Pressure, eGFR - Estimated Glomerular Filtration Rate, LDL - low-density 
lipoprotein, HDL - high-density lipoprotein.
Corresponding 
protein
Total number 
of peptides
Upregulated 
peptides
Downregulated 
peptides
CO1A1_HUMAN 57 9 48
A1AT_HUMAN 41 41 —
CO3A1_HUMAN 34 14 20
B2MG_HUMAN 14 13 1
HBA_HUMAN 13 11 2
CO1A2_HUMAN 10 9 1
FETUA_HUMAN 9 9 —
ALBU_HUMAN 9 9 —
APOA1_HUMAN 7 7 —
HBB_HUMAN 6 5 1
UROM_HUMAN 6 3 3
Table 2. Distribution of deregulated peptides based on protein of origin (top 10 proteins are presented).
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6 proteases, namely CTSD, CTSK, MMP-1, MMP-7, MMP-8 and MMP-13. For 4 proteases (PCSK6, MMP-2, 
MMP-3, MMP-26), opposing expression trends at the mRNA level could be observed in comparison to the pre-
dicted activity changes, whereas in the cases of PCSK5 and PCSK7 the transcriptomics data were inconclusive 
with respect to providing clear expression trends for the respective mRNAs in DN (Table 3).
Literature datasets. We further correlated our predictions with protein expression data on proteases of urinary 
extracellular vesicles (UEVs) in type 1 DN patients, as reported by Musante et al.4. In this study, authors inves-
tigated changes in the expression of 34 proteases and 32 protease inhibitors through analysis of urine samples 
of diabetic patients divided in normo-, micro- and macroalbuminuric groups20. We compared the relative pro-
tein expression change of the reported protease levels between normo- and macroalbuminuric patients with the 
deregulated proteases predicted in our analysis (Table 3). Out of the 4 proteases found to be significantly chang-
ing in disease in both datasets (i.e. our study and the study of Musante et al.4), the predicted deregulation of 3 
(CTSD, MMP-7, MMP-9) was in agreement with the reported protein expression trend and 1 (MMP-3) presented 
opposite trend (Table 3). Collectively, these comparisons to the existing relevant literature did not allow reaching 
conclusive statements with respect to our predictions, in part due to differences in study design (different cases 
and controls in each case), which further enhanced the need for experimental verification of our findings.
Validation of predicted activity of MMP-2 and MMP-9 in DN mouse model through zymography. Given the bio-
logical relevance of the proteases involved (described in the Discussion) and since no objective algorithm for 
prioritizing the findings was available, the generated hypotheses with respect to the activity changes in DN were 
selected for further experimental verification based on assay availability. Specifically, the collagenolytic profile 
(reflecting MMP-2 and MMP-9 activity) of kidney tissue from diabetic, both type 1 (Ins2Akita, Hz/wt) and 2 (Db/
Db), and control mice was analysed by zymography. The mice clearly displayed DN as exemplified by the signif-
icant presence of glomerular PAS positive material and an increased albumin to creatinine ratio (ACR, Fig. 2). 
Representative gel images from each group are presented in Fig. 3. Zymography of kidney extracts from these 
mice showed that the active MMPs and their respective pro-forms were well-separated, with the pro-MMP-9 
identified at 92 kDa, the active MMP-9 at 82 kDa, the pro-MMP-2 identified at 72 kDa and the active MMP-2 at 
66 kDa (Fig. 3A and B - arrows). In case of mice with type 2 diabetes (Db/Db vs. Db/Dm), we report a significant 
0.56 (±0.32) fold decrease of activity of active form of MMP-2 in comparison to the respective controls (Fig. 3C, 
pval < 0.05). In contrast, MMP-2 activity was not significantly changed in type 1 DN (Hz/wt vs. wt/wt). The activ-
ity of MMP-9 decreased in both, type 1 and type 2 DN mice when comparing to the respective controls (Fig. 3D). 
Specifically, for MMP-9, the fold decrease of activity in Db/Db vs. Db/Dm was 0.30 (±0.29, pval < 0.05), and 0.17 
(±0.15, pval < 0.05) in Hz/wt vs. wt/wt comparison supporting the activity predictions from the peptidomics 
analysis.
Protease ↓pept. ↑pept. %freq Score
Transcriptomics expression 
(Nephroseq; in DN vs. controls)
Protein expression (Musante 
et al.4; in DN vs. diabetics)
Activated
CTSD 1 9 80 9.65 increase increase
KLK4 7 100 7.53 — —
PCSK4 7 100 7.53 — —
PCSK5 7 100 7.53 inconclusive* —
PCSK6 7 100 7.53 decrease —
PCSK7 7 100 7.53 inconclusive* —
MMP-7 5 100 5.38 increase increase
CTSK 3 100 3.23 increase —
MMP-26 3 100 3.23 decrease —
MMP-20 2 3 20 1.60 — —
MMP-1 1 2 33 1.51 increase —
Deactivated
MMP-13 10 4 −43 −12.05 decrease no change
MMP-9 10 6 −25 −7.57 — decrease
MMP-2 4 1 −60 −6.36 increase no change
MMP-3 4 1 −60 −6.36 increase increase
MMP-8 5 2 −43 −6.02 decrease no change
MMP-12 4 2 −33 −3.89 — no change
Table 3. List of predicted proteases with calculated activity score. (↓ pept.: number of downregulated peptides, 
↑ pept.: number of upregulated peptides). *Inconclusive: some studies reported increased and some decreased 
levels of the respective protease mRNA in DN (studies are listed in Supplementary Table 4).
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Discussion
Prevalence of diabetic nephropathy is continuously increasing and to date accounts for approximately 50% of 
end-stage renal disease cases worldwide21–24, underscoring the necessity and urgency to identify the mechanisms 
underlying pathogenesis of DN. Proteases are involved in a variety of molecular processes and their strict reg-
ulation is necessary to maintain tissue homeostasis and prevent tissue damage25,26. Thus, careful evaluation of 
proteases in the context of DN appears highly relevant when aiming towards understanding disease pathophysiol-
ogy, even of potential diagnostic or therapeutic value27,28. Histological features of DN, including mesangial ECM 
expansion, thickening of glomerular and tubular basement membrane, tubular atrophy, and interstitial fibrosis, 
suggest changes in proteolytic events in the kidney as directly involved in disease pathogenesis27. Changes in 
glomerular matrix proteins in DN are widely reported and include increased deposition of collagen I, III IV, V, 
fibronectin and entactin29. Nonetheless, knowledge on proteases in DN is still very limited. Through this study, 
we provide a proof of concept for linking urinary peptidomics data to altered protease activity in DN, highlight-
ing several proteases, which could be possible drivers of disease progression and should be further investigated.
Matrix metalloproteinases (MMPs), collectively, are able to degrade every component of ECM and have been 
implicated in renal fibrosis progression30. Their dysregulation was already linked to kidney pathogenesis, includ-
ing DN31. However, given the complexity of MMPs pathobiology, results described in various reports regard-
ing their activity in DN are not always consistent24,31. Specifically, existing differences between protease activity 
reported in cell lines, animal models and human disease (e.g. in case of gelatinases, membrane-type MMPs) are 
being explained by potential diversity in treatment options, analysis of whole kidney versus tissue compartments 
and potentially differing mechanisms responsible for DN development in rodents and human24. In our analysis, 
increase in proteolytic activity of MMP-1, MMP-7, MMP-20, MMP-26 and decreased activity of MMP-2, MMP-3, 
MMP-8, MMP-9, MMP-12 and MMP-13 in DN were predicted.
MMP-2 and MMP-9 are unique among MMPs for preferentially degrading collagen type IV32 – major com-
ponent of tubular basement membrane (TBM)33. As such, activity of these proteases seems of high importance in 
the context of DN development, being specifically related to hallmarks of DN including tubulointerstitial changes 
and the thickening of tubular basement membrane24,34. Activity of MMP-2 and MMP-9 in kidney tissue of dia-
betic patients has not been extensively investigated, however, activity assays in urine indicate their increase in dia-
betes35. In animal models of diabetic kidney disease, decrease in abundance and activity of MMP-2 and MMP-9 
was reported in the early diabetes, while changes in MMP-9 activity are generally not detected in the advanced 
diabetes36. On the other hand, MMP-9 upregulation and increase in activity have been implicated in kidney 
fibrosis initiation through induction of epithelial–mesenchymal transition (EMT)37–39. In agreement with our 
prediction, reduced activity of MMP-2 and MMP-9 in the mouse DN model was observed (both DN type 1 and 
2 for MMP-9 and DN type 2 for MMP-2). Along these lines, decreased activity of MMPs in urinary extracellular 
vesicles (UEVs) of DN patients in comparison to normoalbuminuric diabetic patients, was reported by Musante 
et al.4, leading collectively to the conclusion that kidney damage is associated with reduced activity of MMP-2 
and MMP-9 in diabetic kidney tissue. Validation in human kidney tissue should be considered as a key step in the 
research of the role of these proteases in DN.
Possible activation of matrix metalloproteinase 7 (MMP-7) was reported in several studies (as summarized 
in Table 3), strengthening our prediction. MMP-7 activity in DN has not been extensively studied, however, 
increased tissue expression of MMP-7 has been reported in various kidney diseases (including DN)40. Moreover, 
elevated urinary levels of MMP-7 have been reported in patients with various kidney diseases compared to 
healthy controls and correlated well with renal fibrosis scores. Therefore, MMP-7 has been proposed as a puta-
tive urinary biomarker of kidney fibrosis in CKD and possible mediator of fibrotic events41,42. Along these lines, 
Figure 2. Renal lesions in DN mouse models. Both (A) 4 months old type 1 diabetic mice (Hz/wt) and (B) 
24 weeks old uninephrectomized type 2 diabetic mice (Db/Db) display significantly increased glomerular 
PAS + material and increased urinary albumin to creatinine ratio (ACR) compared to control mice, wt/wt and 
Db/Dm, respectively. N = 6–10 mice. Bar 40 µm.
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peptides that we detected and presumably originated from MMP-7 activity belong to cleaved alpha-1-antitrypsin 
(inhibitor of the following proteases: trypsin, chymotrypsin, and plasminogen activator) and fibrinogen alpha 
chain (monomers of which form the fibrotic tissue)41.
Proteases from the family of lysosomal cathepsins, although linked to tissue fibrosis, are not extensively stud-
ied the context of kidney disease13. Cathepsin D (CTSD), predicted to have increased activity based on our anal-
ysis, contributes to intracellular protein degradation and is known to mediate inflammation and atherosclerotic 
events43. Cysteine proteases i.e. cathepsin B and L take part in CTSD maturation44, the latter being implicated in 
development of early experimental DN45. Fox et al. investigated the role of CTSD in CKD, reporting its increased 
abundance in the human kidney tissue of CKD patients (including DN), especially in the areas of tubular dam-
age. Additionally, activity of CTSD was increased in kidneys of two independent CKD mouse models (unilateral 
ureteric obstruction (UUO) and chronic ischemia reperfusion injury (IRI) vs. respective controls) and its inhi-
bition by pepstatin A effectively reduced interstitial fibrosis46. Similar increase in activity in injured kidney and 
benefits of CTSD inhibition were reported by Cocchiaro et al. in the acute kidney injury (AKI) mouse model47. 
Since cathepsin D is involved in pathways related to collagen degradation and metabolism of angiotensinogen 
to angiotensins48, its increased expression and activity is expected in DN. Moreover, CTSD, which synthesis is 
stimulated by insulin49, was suggested as a novel biomarker of type 2 diabetes risk and insulin resistance (IR)50. 
Nevertheless, Musante et al.4 reported decreased activity of CTSD in exosomes of DN patients in contrast to 
its increased protein levels, collectively underscoring the need for further investigation of this protease and its 
specific role in the context of DN. Interestingly, Kusaka et al. reported increased serum levels of CTSK having 
Figure 3. Zymography for the investigation of MMP-2 and MMP-9 activities. (A) Extracts from four biological 
replicates of DN in type 2 diabetes (T2D; Db/Db) and their respective controls (Db/Dm) were loaded. (B) 
Extracts from four biological replicates of DN in type 1 diabetes (T1D; Hz/wt) and their respective controls (wt/
wt) were loaded. (C) The fold change of MMP-2 activity in DN was assessed relative to the respective controls 
per category: Db/Db (DN in T2D) was compared to Db/m and Hz/wt (DN in T1D) to wt/wt. The mean value 
for Db/Db vs. Db/Dm (activity fold change) was 0.56 ± 0.32 (pval < 0.05), whereas the mean value for Hz/wt 
vs. wt/wt (activity fold change) was 1.46 ± 0.91 (pval > 0.05). (D) The fold change of MMP-9 activity in DN was 
assessed relative to the appropriate controls for each group. (A) Db/Db (DN in T2D) was compared to Db/m 
and Hz/wt (DN in T1D) to wt/wt. The mean value for Db/Db vs. Db/Dm (activity fold change) was 0.30 ± 0.29 
(pval < 0.05), whereas the mean value for Hz/wt vs. wt/wt (activity fold change) was 0.17 ± 0.15 (pval < 0.05). 
Graphical representation of densitometry analysis of the results (mean ± SD) is shown (∗pval < 0.05, Student’s 
t-test).
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positive correlation with nephropathy progression in diabetic patients (assessed based on serum creatinine and 
eGFR measurements)51. A 7-year long follow-up study performed by the same authors concluded that serum 
CTSK levels in type 2 diabetes patients are indicative of vascular endothelial dysfunction and deterioration of 
renal function52. Taken together, cathepsins D and K, both extensively studied for their potential as therapeutic 
targets in e.g. cancer, Alzheimer or Parkinson disease53,54, may have potential as targets for novel DN treatment.
In conclusion, we present a novel approach for the interpretation of changes in urinary peptides, leading 
to prediction of upstream proteolytic events, possibly linking the peptidome profile to tissue proteases in DN. 
Through our analysis, we indicated possible deregulation of several proteases in DN and subsequently verified 
experimentally selected results in the case of MMP-2 and MMP-9 in DN mouse models. Among the weak-
nesses of our study is the relatively low number of protease-associated sequences; their enrichment with more 
disease-associated peptides/potential substrates of these proteases will further increase confidence in the pre-
dicted protease activity trends. A further weakness is the fact that only some of the predicted changes in pro-
tease activity were experimentally verified. We are fully aware that the study of proteases is far more complex: 
for any given enzyme, mRNA, protein and activity levels are not always in agreement, as also evident from the 
data presented here. Hence, the described cross-correlations should be interpreted with caution. Moreover, sub-
strate preference and specificity can be highly variable and complex compensatory mechanisms are activated in 
pathological conditions6. In addition, advanced glycation end products (AGE) can play a role in protease activity 
modulation, further increasing the intricacy55. Nevertheless, our analysis yielded a list of functionally interesting 
findings which should be further investigated in the context of DN progression and could be considered as puta-
tive therapeutic targets. Through our analysis we contribute to a better understanding of the protease role in DN 
and propose multiple proteases of possible significance in disease pathogenesis.
Methods
Patient Population and Data Collection. The urinary CE-MS peptide profiling datasets as well as the clini-
cal data were retrieved from the Human Urinary Proteome database56,57. The study was approved by the ethics com-
mittee from Hannover Medical School, Germany (ID: 3116-2016), fulfilling all the requirements on the protection 
of the individuals participating. Details regarding samples processing, capillary electrophoresis-mass spectrometry 
(CE-MS) analysis, data processing and storage can be found in Supplementary Methods. In brief, urine samples were 
collected from 10 different centres: Steno Diabetes Center (Gentofte, Denmark; n = 63); Austin Health and Northern 
Health, University of Melbourne, (Melbourne, Australia; n = 44); Diabetes Centre of the Isala Clinics, (Zwolle, The 
Netherlands; n = 33); Hannover Medical School (Hannover, Germany; n = 33); Human Nutrition and Metabolism 
Research and Training Center, Karl Franzens University of Graz (Graz, Austria; n = 19); Barbara Davis Center for 
Childhood Diabetes, University of Colorado Denver (Denver, USA; n = 15); Charles University (Prague, Czech 
Republic; n = 10); University Medical Center (Groningen, The Netherlands; n = 9); RD-Néphrologie, Néphrologie 
Dialyse St. Guilhem (Montpellier, France; n = 9) and BHF Glasgow Cardiovascular Research Centre (Glasgow, UK; 
n = 4). Sample collection was performed in accordance to local ethics requirements and all individuals gave written 
informed consent. In all cases, spot urine samples were collected in sterile containers at the time of the study visit. 
One mL aliquots of unprocessed samples were stored at −80 °C prior to being processed as described previously58 
and Supplementary Methods. Samples were frozen within 4 hours of collection. Study participants were diagnosed 
with type 1 or type 2 diabetes mellitus. Diabetic nephropathy was defined by increased urinary albumin excretion 
(UAE) in the absence of other renal diseases. In total, we evaluated urine samples from 239 patients representing 
diabetic patients with nephropathy (n = 121, urinary albumin levels >300 mg/L) and patients without evidence of 
nephropathy (n = 118, urinary albumin levels <30 mg/L). Clinicopathological characteristics of the patients from 
the two groups are summarized in Table 1.
Statistical Analysis. After testing for normal distribution, continuous data were compared by the 
Mann-Whitney test, as this test has proven to be of superior statistical power in peptidomics datasets59. In order 
to control for the false discovery rate at 0.05, the p-values were adjusted by the Benjamini and Hochberg method60 
implemented in the Bioconductor package multtest61. Differential expression was based on a p-value of <0.05 
after correction for multiple testing and a fold change >1.5 for upregulated or <0.66 for downregulated peptides.
Protease Prediction and Protease Activity Prediction. In order to link urinary peptides to the pro-
teases potentially involved in their generation, the open-source tool for protease prediction – Proteasix (www.
proteasix.org)15 was used for the analysis. Briefly, Proteasix uses information about naturally occurring peptides 
i.e. corresponding protein UniProt ID and start and stop amino acid position to predict potential cleaving pro-
teases. Proteasix retrieves information about cleavage sites (CS) from protease databases (MEROPS, BRENDA) 
considering also cleavage site restrictions (from ENZYME database). As a result, a list of predicted proteases 
is generated. Proteases labelled as “Observed” or “Observed in different substrate” (in case given cleavage site 
was identified using different substrate) come from the literature-curated collection of experimentally observed 
cleavage site associations, whereas high/medium/low probability predictions are based on calculation of the prob-
ability of cleavage based on MEROPS protease specificity matrices. In our study, in order to increase reliability 
of predictions, analysis was based only on proteases with observed cleavage sites (Supplementary Table 2). As an 
input for our analysis, the list of the 302 sequenced, differentially expressed peptides (pval < 0.05 and fold change 
>1.5) obtained from the CE-MS analysis was used (Supplementary Table 1). List of predicted proteases is avail-
able in Supplementary Table 2.
For the protease activity prediction the following metrics were calculated:
occ(up): sum of all occurrences for each individual protease in the up-regulated peptides
occ(down): sum of all occurrences for each individual protease in the down-regulated peptides
www.nature.com/scientificreports/
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n(up): total number of peptides being up-regulated
n(down): total number of peptides being down-regulated
+n nweight: (occ(down))/( (down)) (occ(up))/( (up))
= ∗nfreq%(up) (occ(up)/ (total)) 100
= ∗nfreq%(down) (occ(down)/ (total)) 100
= − + ∗%freq %frequency difference ratio[ ] ((freq%(up) freq%(down))/(freq%(up) freq%(down))) 100
= ∗Score % weightfreq
Positive scores indicate potentially activated proteases, while negative scores indicate deactivation 
(Supplementary Table 3).
Prediction Investigation Through Transcriptomics Data Analysis. Nephroseq (www.nephroseq.org, 
University of Michigan, Ann Arbor, MI) is a kidney transcriptomics data repository equipped with tools for 
data analysis and visualization. The list of 17 predicted proteases was uploaded in Nephroseq in the form of 
EntrezGene IDs and corresponding gene expression was checked in the available diabetic nephropathy datasets. 
DN datasets were selected through Primary Filters > Group > Diabetic nephropathy. There were five DN datasets 
on comparison of DN vs. Healthy Living Donor groups (Supplementary Table 4). Significantly deregulated genes 
(pval < 0.05) appearing in those five sets were extracted and differential expression results were compared with the 
predicted proteolytic activity trend.
Mice. Ins2Akita mice were used as a model of type I diabetes and were initially obtained from the Jackson 
Laboratory (US) and further bred in the local animal facility (Toulouse) under SPF conditions. Kidney sam-
ples (~1/6th of the kidney cortex) from 4 months old mice with diabetes (Hz/wt) and wild-type (wt/wt) mice 
were snap frozen after sacrifice. Db/db mice were used as a model of type 2 diabetes. Db/Dm (control) and 
Db/Db (diabetic) mice (Jackson Laboratory (US)) were subjected to right side uninephrectomy (UNx) under 
anesthesia at 8 weeks of age to accelerate development of DN as previously described62. Uninephrectomized 
Db/Dm and Db/Db mice were sacrificed at 24 weeks and kidney samples (~1/6th of the kidney cortex) were 
snap frozen. The animal experiments were approved by the local ethics committee from Toulouse (number 
122-2015-42).
Histology and ACR measurements. Kidneys were fixed in Carnoy solution, dehydrated in alcohol, and 
embedded in paraffin. Two-micrometer sections were stained with periodic acid-Schiff reagent. At least 50 glo-
meruli, including superficial and juxtaglomerullary cortical area, were examined for each animal. The extent 
of glomerular damage was obtained by manual scoring on a scale from 0–4. ACR was measured as described63. 
Briefly: the concentration of creatinine in urine was measured by the colorimetric method of Jaffe according to 
the protocol Creatinine Assay Kit (Bio Assay Systems). The concentration of urinary albumin was measured by 
ELISA using the AlbuWell kit (Exocell).
Zymography. Sample preparation. Frozen kidney tissue (7 to 47 mg) was resuspended in 1x PBS (Gibco), 
pH 7.5 and homogenized with stainless steel beads (Next Advance) in the Bullet Blender Homogenizer (Next 
Advance). Samples were centrifuged (16,000 × g, 10 min, RT) to remove beads and debris. Protein concentration 
was determined by Bradford assay (Bio Rad) in the supernatant which was stored at −80 °C until further use.
Zymography protocol. Zymography was performed in 8% polyacrylamide gels containing 0.2% (w/v) gelatin 
(Porcine gelatin, Sigma Aldrich). Five independent experiments were performed analysing 4 biological replicates 
per group and the obtained data were combined in order to increase the statistical power. The protein amount of 
samples loaded on each well was 50 μg. Reported data include the relative fold change of protease activity among 
each diabetic group compared to the corresponding control, from each independent experiment. Electrophoresis 
was performed in TGS buffer (Bio Rad) (Tris 25 mM, Glycine 192 mM, 0.1% (w/v) SDS, pH 8.3) at 5 mA per gel, 
at room temperature for about 4–5 hours in non-reducing conditions. After electrophoresis, the gels were incu-
bated with the equilibration buffer (25 mM Tris – HCl pH 7.8, Bio Rad, 2.5% (v/v) Triton-X 100, AppliChem) for 
1.5 hours at 4 °C (protein renaturation). Gels were then incubated with the activation buffer (25 mM Tris – HCl 
pH 7.8, Bio Rad, 5 mM CaCl2, Sigma Aldrich) for 24 h at 37 °C followed by a wash with water and fixed with a 
solution of 30% methanol (Fischer), 10% acetic acid (Carlo Erba) for half an hour. Staining was performed for 
30 minutes with Coomassie Brilliant Blue R-250 (Fluka) at room temperature. Finally, the gels were destained 
with water and scanned at a GS-800 imaging densitometer (Bio Rad) in transmission mode. The images were 
analysed with the Quantity One software (Bio Rad).
Data Availability. All data generated or analysed during this study are included in this published article 
(and its Supplementary Information files). As described above, all methods were carried out in accordance with 
relevant guidelines and regulations.
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